ArticleResearch square2025
Identifying and Predicting Cognitive Decline Using Multi-Modal Sensor Data and Machine Learning Approach.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's Disease (AD) remains a critical global health challenge, with its prevalence expected to rise dramatically by 2050, leading to substantial financial and emotional burdens. Mild Cognitive Impairment (MCI), the prodromal stage of AD, presents a crucial opportunity for early intervention, yet its diagnosis remains difficult due to the overlap with normal aging. Traditional diagnostic methods, such as neuroimaging and cerebrospinal fluid analysis, are costly and invasive, highlighting the need for alternative, scalable, and non-invasive biomarkers. This study explores the potential of naturalistic driving behavior as a digital biomarker for detecting cognitive decline in individuals at risk for AD and MCI. A total of 118 participants (8 with AD, 65 with MCI, and 45 cognitively healthy individuals) were included in this study. At baseline year, we measured their demographics, cognitive status administrated by dementia experts, 3 consecutive months of naturalistic driving performance and driving life-space from participants' own vehicle and sleep data via wrist-worn actigraphy, integrated into multi-modal data to feed to XGBoost-based framework. After 1-year follow, their cognitive status was assessed. We implemented a two-phase validation framework: first, classification model using Leave-One-Subject-Out Cross-Validation (LOSO-CV) to classify baseline cognitive status, and then, conducting a prediction model with to assess the model's ability to predict 1-year follow-up cognitive status. Our results demonstrate that the multi-modal classifier achieved strong classification performance (accuracy = 68.64%; precision = 73.97%; F1-score=74.48%), with the highest recall (76.39%) from a model incorporating demographics and driving features, and prediction performance (accuracy = 70.48%; precision = 71.88%; F1-score = 74.80%, recall = 77.97%). Key predictive features included sex, mean awakening duration, age, average acceleration, and sleep efficiency, underscoring the relevance of driving behavior and sleep characteristics in cognitive assessment. By leveraging everyday activities such as driving, this framework provides a novel, non-invasive approach for identifying individuals at risk for cognitive decline. Furthermore, its ability to predict future disease progression establishes a forward-looking paradigm for early detection and monitoring. Beyond cognitive impairment, this methodology offers a scalable and generalizable framework for disease prediction, with potential applications in detecting and monitoring other neurodegenerative and chronic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.